D

espite the outcomes of both the presidential election and the Brexit vote, this could be a banner year for biopharma mergers and acquisitions, according to two new reports.

Biopharma valuations leveled off substantially in 2016, which sets the stage this year for several new divestitures and megadeals, according to a new report from consulting firm EY.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories